These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

475 related items for PubMed ID: 22382615

  • 1. Breast cancer risk during hormone therapy: experimental versus clinical data.
    Ruan X, Seeger H, Mueck AO.
    Minerva Endocrinol; 2012 Mar; 37(1):59-74. PubMed ID: 22382615
    [Abstract] [Full Text] [Related]

  • 2. Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer.
    van Leeuwen FE.
    Acta Endocrinol (Copenh); 1991 Mar; 125 Suppl 1():13-26. PubMed ID: 1801500
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of the proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition.
    Mueck AO, Seeger H, Wallwiener D.
    Climacteric; 2003 Sep; 6(3):221-7. PubMed ID: 14567770
    [Abstract] [Full Text] [Related]

  • 6. Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: a debated clinical issue.
    Gadducci A, Biglia N, Cosio S, Sismondi P, Genazzani AR.
    Gynecol Endocrinol; 2009 Dec; 25(12):807-15. PubMed ID: 19906000
    [Abstract] [Full Text] [Related]

  • 7. Effects of sex steroids on proliferation in normal mammary tissue.
    Söderqvist G.
    Ann Med; 1998 Dec; 30(6):511-24. PubMed ID: 9920352
    [Abstract] [Full Text] [Related]

  • 8. Postmenopausal hormone therapy and breast cancer.
    Prescrire Int; 2009 Apr; 18(100):66-7. PubMed ID: 19585723
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Dose-dependent changes of the ratio of apoptosis to proliferation by norethisterone and medroxyprogesterone acetate in human breast epithelial cells.
    Seeger H, Rakov V, Mueck AO.
    Horm Metab Res; 2005 Aug; 37(8):468-73. PubMed ID: 16138258
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Breast cancer risk with postmenopausal hormonal treatment.
    Collins JA, Blake JM, Crosignani PG.
    Hum Reprod Update; 2005 Aug; 11(6):545-60. PubMed ID: 16150813
    [Abstract] [Full Text] [Related]

  • 17. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results.
    Kuhl H, Stevenson J.
    Gynecol Endocrinol; 2006 Jun; 22(6):303-17. PubMed ID: 16785155
    [Abstract] [Full Text] [Related]

  • 18. Progestogens in postmenopausal hormone therapy and the risk of breast cancer.
    Lambrinoudaki I.
    Maturitas; 2014 Apr; 77(4):311-7. PubMed ID: 24485796
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Progestogens and venous thromboembolism among postmenopausal women using hormone therapy.
    Canonico M, Plu-Bureau G, Scarabin PY.
    Maturitas; 2011 Dec; 70(4):354-60. PubMed ID: 22024394
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.